Influence of omeprazole on multidrug resistance protein 3 expression in human liver

被引:45
作者
Hitzl, M
Klein, K
Zanger, UM
Fritz, P
Nüssler, AK
Neuhaus, P
Fromm, MF
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Robert Bosch Krankenhaus, Dept Pathol, Stuttgart, Germany
[3] Humboldt Univ, Charite, Dept Surg, Berlin, Germany
[4] Univ Erlangen Nurnberg, Inst Expt Clin Pharmacol & Toxicol, Erlangen, Germany
关键词
D O I
10.1124/jpet.102.043547
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance protein (MRP) 3 transports bile salts and conjugated xenobiotics from cells (hepatocytes and enterocytes) into the blood. Hepatic MRP3 expression is low under normal conditions but is markedly up-regulated during cholestasis. Since little is known about additional factors increasing human hepatic MRP3 expression, we investigated the variability of MRP3 expression in a large collection of human livers and factors contributing to variable MRP3 expression in liver and HepG2 cells. MRP3 was measured in 62 human livers from patients with and without omeprazole treatment and in HepG2 cells with and without omeprazole or beta-naphthoflavone treatment. Livers of patients treated with omeprazole showed 4.8-fold (P < 0.0001) higher MRP3 protein expression compared with the remainder of the population. Accordingly, MRP3 mRNA and protein were induced 2.4- and 1.8-fold, respectively (P < 0.01 and P < 0.05), in HepG2 cells treated with omeprazole. Finally, MRP3 was induced in HepG2 cells by β-naphthoflavone. In summary, treatment with omeprazole and β-naphthoflavone is a determinant of variable human hepatic MRP3 expression.
引用
收藏
页码:524 / 530
页数:7
相关论文
共 35 条
  • [1] Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells
    Backlund, M
    Johansson, I
    Mkrtchian, S
    IngelmanSundberg, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (50) : 31755 - 31763
  • [2] A family of drug transporters: The multidrug resistance-associated proteins
    Borst, P
    Evers, R
    Kool, M
    Wijnholds, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16): : 1295 - 1302
  • [3] OMEPRAZOLE, AN INDUCER OF HUMAN CYP1A1 AND 1A2, IS NOT A LIGAND FOR THE AH RECEPTOR
    DAUJAT, M
    PERYT, B
    LESCA, P
    FOURTANIER, G
    DOMERGUE, J
    MAUREL, P
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 188 (02) : 820 - 825
  • [4] Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver
    Donner, MG
    Keppler, D
    [J]. HEPATOLOGY, 2001, 34 (02) : 351 - 359
  • [5] Regulation of dioxin receptor function by omeprazole
    Dzeletovic, N
    McGuire, J
    Daujat, M
    Tholander, J
    Ema, M
    FujiiKuriyama, Y
    Bergman, J
    Maurel, P
    Poellinger, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (19) : 12705 - 12713
  • [6] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    Fellay, J
    Marzolini, C
    Meaden, ER
    Back, DJ
    Buclin, T
    Chave, JP
    Decosterd, LA
    Furrer, H
    Opravil, M
    Pantaleo, G
    Retelska, D
    Ruiz, L
    Schinkel, AH
    Vernazza, P
    Eap, CB
    Telenti, A
    [J]. LANCET, 2002, 359 (9300) : 30 - 36
  • [7] Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69
  • [8] Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine
    Fromm, MF
    Kim, RB
    Stein, CM
    Wilkinson, GR
    Roden, DM
    [J]. CIRCULATION, 1999, 99 (04) : 552 - 557
  • [9] Gotoh Y, 2000, J PHARMACOL EXP THER, V292, P433
  • [10] The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    Greiner, B
    Eichelbaum, M
    Fritz, P
    Kreichgauer, HP
    Von Richter, O
    Zundler, J
    Kroemer, HK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 147 - 153